Back to search
Search Results 1-10 of 47 clinical trials found.
This prospective, concurrent controlled, open-label, multicenter study is designed to collect
additional safety data through 5 years of follow-up for subjects randomized to either the
treatment arm (PRESERFLO® MicroShunt with MMC) or the control arm (Trabeculectomy with MMC)
of the INN-005 clinical study.
This is a prospective, multicenter, single-arm, open-label clinical study of the commercially
available TECNIS Toric II IOL. The study will be conducted in up to 192 subjects needing
unilateral or bilateral cataract surgery in up to 8 sites in United States (US). The subjects
will be followed for up to 3-months postoperatively.
The objectives of this study are to evaluate the safety and efficacy of Zimura intravitreal
administration in patients with geographic atrophy secondary to age-related macular
The purpose of this study is to compare the efficacy and safety of ABP 938 versus Aflibercept
(Eylea®) in the treatment of neovascular age-related macular degeneration. Subjects will be
randomized in a masked 1:1 ratio to receive 2 mg (0.05 mL) of either ABP 938 (Treatment Group
A) or aflibercept (Treatment Group B) administered by intravitreal (IVT) injection.
Objective: To investigate the efficacy of microblepharoexfoliation by BlephEx™ as an adjunct
to eyelid cleansing in the treatment of anterior blepharitis and to validate the grading
score of lid contamination to describe the severity of anterior blepharitis. Design: A
prospective, randomized, paired-eye trial. Methods: One of patients' eyes will be randomized
into the microblepharoexfoliation group which will use the BlephExTM device during the
in-house lid cleansing procedure. The other eye will be in the control group which will
receive conventional lid cleansing. The parameters indicating the efficacy of the
microblepharoexfoliation procedure including the symptom scoring system; the Standard Patient
Evaluation of Eye Dryness Questionnaire (SPEED), lashes contamination, lid margin redness,
number of preservative free artificial tears used per day, meibomian gland quality and
expressibility will be recorded at the screening ...
The objective of this study is to investigate the effect of K-321 in patients with Fuchs
endothelial corneal dystrophy (FECD) after descemetorhexis.
The purpose of this observational research study is to follow participants who have been
treated with either AU-011 or observation and/or received standard of care therapy while
participating in a previous Aura Biosciences clinical research study to assess the long-term
safety and effectiveness of AU-011 and standard of care therapy. This study will collect
information from procedures conducted as part of routine follow-up eye care and cancer care.
Back to search